secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ainos, Inc. (AIMD)
CIK:        0001014763
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001493152-24-030263
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ainos Q2 2024 net loss widens to $3.2M; revenues nil; FCGS trial begins
-----------------------------------------------------------------------

- Revenues nil vs $28,555 YoY as COVID-19 test kit sales ceased; net loss $3,195,022 vs $2,349,727.
- Cash $8,014,098 at June 30, 2024, after $9M convertible note in May and prepayment of senior secured note.
- Enrolled first subject for VELDONA-based FCGS clinical study in July; 30-subject trial aims for Q1 2025 completion.
- Next-Gen Ainos Flora VOC POCT with NVIDIA CUDA targets Q3 design completion, Q4 clinical trial kickoff.
- Operating expenses rose to $3,023,636 from $2,289,336 YoY, driven by co-research, staff, and stock-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1014763/000149315224030263/0001493152-24-030263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1014763/000149315224030263/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer